Business Description
Madrigal Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US5588681057
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 5.41 | |||||
Equity-to-Asset | 0.63 | |||||
Debt-to-Equity | 0.29 | |||||
Debt-to-EBITDA | -0.33 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -13 | |||||
3-Year EPS without NRI Growth Rate | -15.2 | |||||
3-Year FCF Growth Rate | -19.5 | |||||
3-Year Book Growth Rate | 9.6 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 72.02 | |||||
9-Day RSI | 57.34 | |||||
14-Day RSI | 51.46 | |||||
6-1 Month Momentum % | 65.45 | |||||
12-1 Month Momentum % | -17.97 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.38 | |||||
Quick Ratio | 5.38 | |||||
Cash Ratio | 5.35 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.6 | |||||
Shareholder Yield % | -1.37 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -212.62 | |||||
ROA % | -99.58 | |||||
ROIC % | -2709.35 | |||||
ROC (Joel Greenblatt) % | -20062.15 | |||||
ROCE % | -134.29 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 11.27 | |||||
Price-to-Tangible-Book | 11.27 | |||||
EV-to-EBIT | -12.12 | |||||
EV-to-Forward-EBIT | -6.58 | |||||
EV-to-EBITDA | -12.14 | |||||
EV-to-Forward-EBITDA | -6.6 | |||||
EV-to-Forward-Revenue | 49 | |||||
EV-to-FCF | -13.43 | |||||
Price-to-Net-Current-Asset-Value | 11.36 | |||||
Price-to-Net-Cash | 11.45 | |||||
Earnings Yield (Greenblatt) % | -8.25 | |||||
FCF Yield % | -6.66 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Madrigal Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -18.529 | ||
Beta | 1.05 | ||
Volatility % | 69.88 | ||
14-Day RSI | 51.46 | ||
14-Day ATR (€) | 10.723556 | ||
20-Day SMA (€) | 207.435 | ||
12-1 Month Momentum % | -17.97 | ||
52-Week Range (€) | 112.6 - 295 | ||
Shares Outstanding (Mil) | 21.28 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Madrigal Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Madrigal Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Madrigal Pharmaceuticals Inc Frequently Asked Questions
What is Madrigal Pharmaceuticals Inc(FRA:YDO1)'s stock price today?
When is next earnings date of Madrigal Pharmaceuticals Inc(FRA:YDO1)?
Does Madrigal Pharmaceuticals Inc(FRA:YDO1) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |